Title

Evaluating Anticancer Activity of a Cobalt(III) Complex with a Thiosemicarbazone Ligand Against Triple Negative Breast Cancer Cells

Description/Abstract/Artist Statement

Cancer is one of the major causes of death in the world. Breast cancer is an uncontrolled growth of epithelial cells of the breast. Triple negative breast cancer (TNBC), a subtype of breast cancer, lacks estrogen, progesterone, and HER2 receptors. Chemotherapeutic options for TNBC which involves cisplatin have severe side effects, e.g., cytotoxicity of normal breast tissue, drug resistance, and breast cancer recurrence. The objective of this study was to determine less toxic treatment options for TNBC by using a cobalt(III) complex, which like most conventional anticancer drugs was designed to disrupt DNA synthesis as a chemotherapeutic agent. Previously, [Co(phen)2(H2O)2](NO3)3 1 (where phen = 1,10-phenanthroline) was reacted with 9-anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) to produce [Co(phen)2(MeATSC)](NO3)3·1.5H2O·C2H5OH 2. The hypothesis is as follows: complex 2 will have a higher anticancer effect on TNBC cell line MDA-MB-231-VIM-RFP than cisplatin. In vitro cytotoxicity studies involving complex 2 with MDA-MB-231-VIM-RFP were carried out by using the Cell Counting Kit-8 (CCK-8) assay. The anti-proliferative activity of complex 2 was evaluated after incubating the drug with MDA-MB-231-VIM-RFP cells in increasing concentrations (0, 6.125, 12.5, 25, 50, and 100 μM) for 24 hours, then cell viability was measured by CCK-8 assay. Dose curves and doses required to inhibit 50% of cell growth (IC50 values) were obtained by using Origin Pro software, which revealed that MDA-MB-231-VIM-RFP cell viability was negatively impacted by complex 2 with an IC50 value of ~26 μM.

Presenting Author Name/s

Lindsay Days

Faculty Advisor/Mentor

Alvin Holder

College Affiliation

College of Sciences

Presentation Type

Oral Presentation

Disciplines

Biochemistry, Biophysics, and Structural Biology | Cell and Developmental Biology | Chemistry

Session Title

Monarchs Maximizing Access to Research Careers #2

Location

Zoom Room I

Start Date

3-20-2021 10:00 AM

End Date

3-20-2021 10:55 AM

This document is currently not available here.

Share

COinS
 
Mar 20th, 10:00 AM Mar 20th, 10:55 AM

Evaluating Anticancer Activity of a Cobalt(III) Complex with a Thiosemicarbazone Ligand Against Triple Negative Breast Cancer Cells

Zoom Room I

Cancer is one of the major causes of death in the world. Breast cancer is an uncontrolled growth of epithelial cells of the breast. Triple negative breast cancer (TNBC), a subtype of breast cancer, lacks estrogen, progesterone, and HER2 receptors. Chemotherapeutic options for TNBC which involves cisplatin have severe side effects, e.g., cytotoxicity of normal breast tissue, drug resistance, and breast cancer recurrence. The objective of this study was to determine less toxic treatment options for TNBC by using a cobalt(III) complex, which like most conventional anticancer drugs was designed to disrupt DNA synthesis as a chemotherapeutic agent. Previously, [Co(phen)2(H2O)2](NO3)3 1 (where phen = 1,10-phenanthroline) was reacted with 9-anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) to produce [Co(phen)2(MeATSC)](NO3)3·1.5H2O·C2H5OH 2. The hypothesis is as follows: complex 2 will have a higher anticancer effect on TNBC cell line MDA-MB-231-VIM-RFP than cisplatin. In vitro cytotoxicity studies involving complex 2 with MDA-MB-231-VIM-RFP were carried out by using the Cell Counting Kit-8 (CCK-8) assay. The anti-proliferative activity of complex 2 was evaluated after incubating the drug with MDA-MB-231-VIM-RFP cells in increasing concentrations (0, 6.125, 12.5, 25, 50, and 100 μM) for 24 hours, then cell viability was measured by CCK-8 assay. Dose curves and doses required to inhibit 50% of cell growth (IC50 values) were obtained by using Origin Pro software, which revealed that MDA-MB-231-VIM-RFP cell viability was negatively impacted by complex 2 with an IC50 value of ~26 μM.